In vitro experiments show nebivolol improves cytotoxicity in T cells against breast cancer, suggesting a new treatment strategy.
These findings show that nebivolol reinvigorates CD4+ and CD8+ T cells following repeated activation, restoring their cytotoxic function against breast cancer cells in vitro. The immunomodulatory activity of Nebivolol is independent of β1-AR and mediated through β2-AR, suggesting that biased β₂-AR signaling may represent a potential strategy for modulating T cell exhaustion in the tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Hajiaghayi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: